Long acting GLP-1 receptor agonist (injectable)
Liraglutide 0.9 mg injection once daily
LIRA_SC_0p9MG_QD
Related
- All doses pooled: Liraglutide injection
- Liraglutide 1.8 mg subcutaneous once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 3.0 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide flexible dose injection once daily
- Liraglutide 1.2 mg subcutaneous once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg subcutaneous once daily
- Liraglutide subcutaneous once daily, flexible dose: 1.2 or 1.8 mg by tolerability
- Liraglutide 2.4 mg injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide maximum tolerated dose injection once daily
- Liraglutide 0.6 mg injection
- Liraglutide 1.2 mg injection
- Liraglutide 1.25UG/KG injection once daily
- Liraglutide 5.0UG/KG injection once daily
- Liraglutide 7.5UG/KG injection once daily
- Liraglutide 10UG/KG injection once daily
- Liraglutide 12.5UG/KG injection once daily
- Liraglutide 0.3 mg injection once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.89 (-1.29 to -0.49) | 0.51 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.29 (-1.62 to -0.94) | 0.99 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.31 (-1.63 to -0.54) | 0.57 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.33 (-3.81 to 1.19) | 0.56 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.10 (-1.49 to -0.70) | 0.62 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.19 (-1.84 to 0.07) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 1.05 (-0.73 to 2.78) | 0.22 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.25 (-1.37 to 0.84) | 0.46 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 1.04 (-1.13 to 5.23) | 0.27 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 1.56 (-2.07 to 5.88) | 0.32 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Dulaglutide 0.75 mg subcutaneous once weekly | MD 0.04 (-4.89 to 4.93) | 0.36 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.26 (-1.19 to 1.72) | 0.26 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 1.95 (0.37 to 8.51) | 0.24 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 11.20 (4.03 to 26.04) | 0.70 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 3.80 (0.77 to 12.07) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.07 (0.00 to 1.43) | 0.76 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.02 (0.15 to 4.84) | 0.69 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.18 (0.46 to 2.83) | 0.57 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.81 (0.45 to 57.10) | 0.18 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.27 (-4.05 to -0.45) | 0.51 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 0.92 (-3.45 to 5.39) | 0.69 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -4.20 (-10.42 to 1.98) | 0.69 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD 1.18 (-1.10 to 3.58) | 0.07 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 0.07 (0.00 to 0.91) | 0.01 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 0.38 (0.01 to 10.71) | 0.17 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 0.18 (-1.13 to 1.52) | 0.54 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.78 (0.39 to 1.48) | 0.61 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.44 (0.10 to 1.62) | 0.82 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.66 (0.91 to 2.93) | 0.67 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.46 (0.04 to 2.78) | 0.84 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.39 (0.87 to 2.17) | 0.57 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.83 (1.10 to 3.05) | 0.46 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.16 (0.21 to 23.65) | 0.45 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.60 (0.06 to 5.29) | 0.55 |
Trials
- S00306819 randomized · 36 weeks
- S0034362023 · 150 randomized · 24 weeks
- PIONEER 9Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes2017 · 243 randomized · 52 weeks
- NCT02505334A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus2015 · 466 randomized · 26 weeks
- S0029042014 · 120 randomized · 24 weeks
- S0030062013 · 60 randomized · 24 weeks
- NCT01733758A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus2013 · 494 randomized · 52 weeks
- NCT01558271A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus2012 · 492 randomized · 52 weeks
- S0030722011 · 122 randomized · 12 weeks
- S0030712010 · 99 randomized · 24 weeks
- NCT00395746Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes2006 · 267 randomized · 52 weeks
- NCT00393718Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes2006 · 411 randomized · 52 weeks